Active substance
Pancreatin
- SFDA 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Creon | 150 mg | Capsule · Oral use | 100 Blister | SAR 94.85 | NCE · Prescription | Abbott Laboratories GmbH | Valid |
Safety signals and safety-related labeling changes
- EMA PRAC 7 May 2026 PRAC signal: Infection due to viral transmission
Action for MAH: update of the product information: Yes - EMA PRAC 2 Oct 2025 PRAC signal: Infection due to viral transmission
Action for MAH: update of the product information: No
Combinations containing Pancreatin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.